The resistance of BRCA-deficient tumors to chemotherapy treatments, including PARP inhibitors, is closely associated with restoration of replication fork protection, prompting a significant effort to understand how replication fork dynamics impacts on cancer treatments [121,122]. The gene discussed is PARP1; the disease is cancer.